Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Anti-BCMA CAR T-Cell Therapy in Multiple Myeloma. Reply.

Raje N, Hege K, Kochenderfer JN.

N Engl J Med. 2019 Jul 18;381(3):e6. doi: 10.1056/NEJMc1907520. No abstract available.

PMID:
31314982
2.

Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics.

Panch SR, Srivastava SK, Elavia N, McManus A, Liu S, Jin P, Highfill SL, Li X, Dagur P, Kochenderfer JN, Fry TJ, Mackall CL, Lee D, Shah NN, Stroncek DF.

Mol Ther. 2019 Jul 3;27(7):1275-1285. doi: 10.1016/j.ymthe.2019.05.015. Epub 2019 May 30.

PMID:
31178392
3.

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.

Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN.

N Engl J Med. 2019 May 2;380(18):1726-1737. doi: 10.1056/NEJMoa1817226.

PMID:
31042825
4.

Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus.

Kansal R, Richardson N, Neeli I, Khawaja S, Chamberlain D, Ghani M, Ghani QU, Balazs L, Beranova-Giorgianni S, Giorgianni F, Kochenderfer JN, Marion T, Albritton LM, Radic M.

Sci Transl Med. 2019 Mar 6;11(482). pii: eaav1648. doi: 10.1126/scitranslmed.aav1648.

PMID:
30842314
5.

T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy.

Yamamoto TN, Lee PH, Vodnala SK, Gurusamy D, Kishton RJ, Yu Z, Eidizadeh A, Eil R, Fioravanti J, Gattinoni L, Kochenderfer JN, Fry TJ, Aksoy BA, Hammerbacher JE, Cruz AC, Siegel RM, Restifo NP, Klebanoff CA.

J Clin Invest. 2019 Feb 25;129(4):1551-1565. doi: 10.1172/JCI121491. eCollection 2019 Feb 25.

6.

Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.

Brudno JN, Kochenderfer JN.

Blood Rev. 2019 Mar;34:45-55. doi: 10.1016/j.blre.2018.11.002. Epub 2018 Nov 14. Review.

PMID:
30528964
7.

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.

Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV, Porter DL, Maloney DG, Grupp SA, Mackall CL, June CH, Bishop MR.

J Immunother Cancer. 2018 Dec 4;6(1):137. doi: 10.1186/s40425-018-0460-5. Review.

8.

Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience.

Cornetta K, Duffy L, Feldman SA, Mackall CL, Davila ML, Curran KJ, Junghans RP, Tang JY, Kochenderfer JN, O'Cearbhaill R, Archer G, Kiem HP, Shah NN, Delbrook C, Kaplan R, Brentjens RJ, Rivière I, Sadelain M, Rosenberg SA.

Mol Ther Methods Clin Dev. 2018 Aug 17;10:371-378. doi: 10.1016/j.omtm.2018.08.006. eCollection 2018 Sep 21.

9.

Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL.

Rossi J, Paczkowski P, Shen YW, Morse K, Flynn B, Kaiser A, Ng C, Gallatin K, Cain T, Fan R, Mackay S, Heath JR, Rosenberg SA, Kochenderfer JN, Zhou J, Bot A.

Blood. 2018 Aug 23;132(8):804-814. doi: 10.1182/blood-2018-01-828343. Epub 2018 Jun 12.

10.

T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.

Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, Lam N, Stetler-Stevenson M, Salem D, Yuan C, Pavletic S, Kanakry JA, Ali SA, Mikkilineni L, Feldman SA, Stroncek DF, Hansen BG, Lawrence J, Patel R, Hakim F, Gress RE, Kochenderfer JN.

J Clin Oncol. 2018 Aug 1;36(22):2267-2280. doi: 10.1200/JCO.2018.77.8084. Epub 2018 May 29.

11.

The impact of antibiotic usage on the efficacy of chemoimmunotherapy is contingent on the source of tumor-reactive T cells.

Kuczma MP, Ding ZC, Li T, Habtetsion T, Chen T, Hao Z, Bryan L, Singh N, Kochenderfer JN, Zhou G.

Oncotarget. 2017 Dec 5;8(67):111931-111942. doi: 10.18632/oncotarget.22953. eCollection 2017 Dec 19.

12.

CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile.

Magalhaes I, Kalland I, Kochenderfer JN, Österborg A, Uhlin M, Mattsson J.

J Immunother. 2018 Feb/Mar;41(2):73-83. doi: 10.1097/CJI.0000000000000193.

PMID:
29315094
13.

Chimeric antigen receptor T-cell therapies for multiple myeloma.

Mikkilineni L, Kochenderfer JN.

Blood. 2017 Dec 14;130(24):2594-2602. doi: 10.1182/blood-2017-06-793869. Epub 2017 Sep 19. Review.

14.

Chimeric antigen receptor T-cell therapies for lymphoma.

Brudno JN, Kochenderfer JN.

Nat Rev Clin Oncol. 2018 Jan;15(1):31-46. doi: 10.1038/nrclinonc.2017.128. Epub 2017 Aug 31. Review.

PMID:
28857075
15.

Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.

Alabanza L, Pegues M, Geldres C, Shi V, Wiltzius JJW, Sievers SA, Yang S, Kochenderfer JN.

Mol Ther. 2017 Nov 1;25(11):2452-2465. doi: 10.1016/j.ymthe.2017.07.013. Epub 2017 Jul 27.

16.

Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.

Kochenderfer JN, Somerville RPT, Lu T, Yang JC, Sherry RM, Feldman SA, McIntyre L, Bot A, Rossi J, Lam N, Rosenberg SA.

Mol Ther. 2017 Oct 4;25(10):2245-2253. doi: 10.1016/j.ymthe.2017.07.004. Epub 2017 Jul 13.

17.

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.

Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J, Xue A, Goff SL, Yang JC, Sherry RM, Klebanoff CA, Kammula US, Sherman M, Perez A, Yuan CM, Feldman T, Friedberg JW, Roschewski MJ, Feldman SA, McIntyre L, Toomey MA, Rosenberg SA.

J Clin Oncol. 2017 Jun 1;35(16):1803-1813. doi: 10.1200/JCO.2016.71.3024. Epub 2017 Mar 14.

18.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.

Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV.

J Immunother Cancer. 2016 Dec 20;4:90. doi: 10.1186/s40425-016-0188-z. eCollection 2016.

19.

A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies.

Lu TL, Pugach O, Somerville R, Rosenberg SA, Kochenderfer JN, Better M, Feldman SA.

Hum Gene Ther Methods. 2016 Dec;27(6):209-218. Erratum in: Hum Gene Ther Methods. 2017 Apr;28(2):100.

20.

T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.

Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, Brudno JN, Stetler-Stevenson M, Feldman SA, Hansen BG, Fellowes VS, Hakim FT, Gress RE, Kochenderfer JN.

Blood. 2016 Sep 29;128(13):1688-700. doi: 10.1182/blood-2016-04-711903. Epub 2016 Jul 13.

21.

Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies.

Sabatino M, Hu J, Sommariva M, Gautam S, Fellowes V, Hocker JD, Dougherty S, Qin H, Klebanoff CA, Fry TJ, Gress RE, Kochenderfer JN, Stroncek DF, Ji Y, Gattinoni L.

Blood. 2016 Jul 28;128(4):519-28. doi: 10.1182/blood-2015-11-683847. Epub 2016 May 25.

22.

Toxicities of chimeric antigen receptor T cells: recognition and management.

Brudno JN, Kochenderfer JN.

Blood. 2016 Jun 30;127(26):3321-30. doi: 10.1182/blood-2016-04-703751. Epub 2016 May 20. Review.

23.

Pigmented villonodular synovitis mimics metastases on fluorine 18 fluorodeoxyglucose position emission tomography-computed tomography.

Elumogo CO, Kochenderfer JN, Civelek AC, Bluemke DA.

Quant Imaging Med Surg. 2016 Apr;6(2):218-23. doi: 10.21037/qims.2016.01.04.

24.

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.

Brudno JN, Somerville RP, Shi V, Rose JJ, Halverson DC, Fowler DH, Gea-Banacloche JC, Pavletic SZ, Hickstein DD, Lu TL, Feldman SA, Iwamoto AT, Kurlander R, Maric I, Goy A, Hansen BG, Wilder JS, Blacklock-Schuver B, Hakim FT, Rosenberg SA, Gress RE, Kochenderfer JN.

J Clin Oncol. 2016 Apr 1;34(10):1112-21. doi: 10.1200/JCO.2015.64.5929. Epub 2016 Jan 25.

25.

Versatile strategy for controlling the specificity and activity of engineered T cells.

Ma JS, Kim JY, Kazane SA, Choi SH, Yun HY, Kim MS, Rodgers DT, Pugh HM, Singer O, Sun SB, Fonslow BR, Kochenderfer JN, Wright TM, Schultz PG, Young TS, Kim CH, Cao Y.

Proc Natl Acad Sci U S A. 2016 Jan 26;113(4):E450-8. doi: 10.1073/pnas.1524193113. Epub 2016 Jan 12.

26.

Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD.

Jacoby E, Yang Y, Qin H, Chien CD, Kochenderfer JN, Fry TJ.

Blood. 2016 Mar 10;127(10):1361-70. doi: 10.1182/blood-2015-08-664250. Epub 2015 Dec 11.

27.

IL-12 conditioning improves retrovirally mediated transduction efficiency of CD8+ T cells.

Andrijauskaite K, Suriano S, Cloud CA, Li M, Kesarwani P, Stefanik LS, Moxley KM, Salem ML, Garrett-Mayer E, Paulos CM, Mehrotra S, Kochenderfer JN, Cole DJ, Rubinstein MP.

Cancer Gene Ther. 2015 Jul;22(7):360-7. doi: 10.1038/cgt.2015.28. Epub 2015 Jul 17.

28.

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL.

Lancet. 2015 Feb 7;385(9967):517-528. doi: 10.1016/S0140-6736(14)61403-3. Epub 2014 Oct 13.

PMID:
25319501
29.

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, Goy A, Feldman T, Spaner DE, Wang ML, Chen CC, Kranick SM, Nath A, Nathan DA, Morton KE, Toomey MA, Rosenberg SA.

J Clin Oncol. 2015 Feb 20;33(6):540-9. doi: 10.1200/JCO.2014.56.2025. Epub 2014 Aug 25.

30.

Use of the piggyBac transposon to create stable packaging cell lines for the production of clinical-grade self-inactivating γ-retroviral vectors.

Feldman SA, Xu H, Black MA, Park TS, Robbins PF, Kochenderfer JN, Morgan RA, Rosenberg SA.

Hum Gene Ther Methods. 2014 Aug;25(4):253-60. doi: 10.1089/hgtb.2014.071.

31.

Genetic engineering of T cells in leukemia and lymphoma.

Kochenderfer JN.

Clin Adv Hematol Oncol. 2014 Mar;12(3):190-2. No abstract available.

PMID:
24927269
32.

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.

Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler DH, Hardy NM, Mato AR, Hickstein DD, Gea-Banacloche JC, Pavletic SZ, Sportes C, Maric I, Feldman SA, Hansen BG, Wilder JS, Blacklock-Schuver B, Jena B, Bishop MR, Gress RE, Rosenberg SA.

Blood. 2013 Dec 12;122(25):4129-39. doi: 10.1182/blood-2013-08-519413. Epub 2013 Sep 20.

33.

Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.

Kochenderfer JN, Rosenberg SA.

Nat Rev Clin Oncol. 2013 May;10(5):267-76. doi: 10.1038/nrclinonc.2013.46. Epub 2013 Apr 2. Review.

34.

B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.

Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, Gress RE, Hakim FT, Kochenderfer JN.

Clin Cancer Res. 2013 Apr 15;19(8):2048-60. doi: 10.1158/1078-0432.CCR-12-2422. Epub 2013 Jan 23.

35.

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA.

Blood. 2012 Mar 22;119(12):2709-20. doi: 10.1182/blood-2011-10-384388. Epub 2011 Dec 8.

36.

Chimeric antigen receptor-modified T cells in CLL.

Kochenderfer JN, Rosenberg SA.

N Engl J Med. 2011 Nov 17;365(20):1937-8; author reply 1938. doi: 10.1056/NEJMc1111004. No abstract available.

37.

Personalized cell transfer immunotherapy for B-cell malignancies and solid cancers.

Rosenberg SA, Kochenderfer JN.

Mol Ther. 2011 Nov;19(11):1928-30. doi: 10.1038/mt.2011.223. No abstract available.

38.

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, Morgan RA, Rosenberg SA.

Blood. 2010 Nov 18;116(20):4099-102. doi: 10.1182/blood-2010-04-281931. Epub 2010 Jul 28.

39.

Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a "modified" step-filtration process for clearance of packaging cells.

Feldman SA, Goff SL, Xu H, Black MA, Kochenderfer JN, Johnson LA, Yang JC, Wang Q, Parkhurst MR, Cross S, Morgan RA, Cornetta K, Rosenberg SA.

Hum Gene Ther. 2011 Jan;22(1):107-15. doi: 10.1089/hum.2010.064. Epub 2010 Dec 12.

40.

Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.

Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA.

Blood. 2010 Nov 11;116(19):3875-86. doi: 10.1182/blood-2010-01-265041. Epub 2010 Jul 14.

41.

A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity.

Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X, Sadelain M, Eshhar Z, Rosenberg SA, Morgan RA.

J Immunol. 2009 Nov 1;183(9):5563-74. doi: 10.4049/jimmunol.0900447.

42.

Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.

Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, Wilson WH, Rosenberg SA.

J Immunother. 2009 Sep;32(7):689-702. doi: 10.1097/CJI.0b013e3181ac6138.

43.

A comparison and critical analysis of preclinical anticancer vaccination strategies.

Kochenderfer JN, Gress RE.

Exp Biol Med (Maywood). 2007 Oct;232(9):1130-41. Review.

PMID:
17895521
44.

Maximizing CD8+ T cell responses elicited by peptide vaccines containing CpG oligodeoxynucleotides.

Kochenderfer JN, Chien CD, Simpson JL, Gress RE.

Clin Immunol. 2007 Aug;124(2):119-30. Epub 2007 Jun 21.

46.
47.

Sampling considerations for establishment of baseline loadings from forested watersheds for TMDL application.

Edwards PJ, Williard KW, Kochenderfer JN.

Environ Monit Assess. 2004 Nov;98(1-3):201-23.

PMID:
15473537
48.

Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression.

Kochenderfer JN, Kobayashi S, Wieder ED, Su C, Molldrem JJ.

Blood. 2002 Nov 15;100(10):3639-45. Epub 2002 Jul 5.

PMID:
12393644
49.

Leukemia vaccines.

Kochenderfer JN, Molldrem JJ.

Curr Oncol Rep. 2001 May;3(3):193-200. Review.

PMID:
11296128

Supplemental Content

Loading ...
Support Center